Pernix Therapeutics Holdings Revenue and Competitors

License our Company Data API

Morristown, NJ USA

Location

$99M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

Pernix Therapeutics Holdings's total funding is $99M.

Employee Data

Pernix Therapeutics Holdings's People

Name	Title	Email/Phone

Pernix Therapeutics Holdings Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 Laboratory Rese...	$5M	25	-11%	N/A	N/A
#2 Averitas Pharma	$35.8M	178	8%	N/A	N/A
#3 Somerset Therap...	$5.4M	27	-25%	N/A	N/A
#4 Catalent	$4180M	14516	1%	$550M	N/A
#5 Soterius	$12.5M	62	15%	N/A	N/A
#6 Aquestive Thera...	$6.7M	119	-37%	$199.6M	N/A
#7 MSD Animal Heal...	$9.4M	47	7%	N/A	N/A
#8 Aucta Pharmaceu...	$10.3M	51	6%	N/A	N/A
#9 HealthSTAR Comm...	$106.3M	529	16%	N/A	N/A
#10 B Positive Plas...	$15.5M	77	20%	N/A	N/A

Add Company

Show More Pharma Companies

What Is Pernix Therapeutics Holdings?

Pernix Therapeutics is an integrated specialty pharmaceutical company with development and commercial capabilities focused primarily on the pediatric market. Since our foundation, we have focused on the acquisition, development, marketing and distribution of pharmaceutical products that provide timely and cost effective market entry through various regulatory pathways. All of our products and strategies are focused on creating solid intellectual property to protect the investment and development of our products

keywords:N/A

$99M

Total Funding

N/A

Number of Employees

N/A

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pernix Therapeutics Holdings News

2015-04-17 - Pernix Therapeutics Announces Pricing of Private Offering of $130 Million of 4.25% Convertible Senior Notes Due 2021

Morristown, New Jersey, April 17, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (the “Company”) today announced that it has priced a private offering of $130 million aggregate principal amount of the Company’s 4.25% Convertible Senior Notes due 2021, which will be sold only to qualifie ...

2014-08-20 - Pernix Therapeutics Closes on Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.

MORRISTOWN, NJ, August 20, 2014 – Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with ...

Other Companies in Morristown

Company Name	Revenue	Number of Employees	Employee Growth	Total Funding
#1 Diversified Sof...	$0.1M	2	0%	N/A
#2 Triple S Corp	$0.2M	2	-99%	N/A
#3 medEchat	$0.1M	2	0%	N/A
#4 West View Middl...	N/A	3	-70%	N/A
#5 TwineSocial	$0.2M	3	N/A	N/A